A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

Completed · Phase 2 · Has a placebo group

Conditions studied: Pleural Effusion

In brief

The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.

Key facts

Study ID
NCT04159831
Run by
Rein Therapeutics
People needed
44
Starts
2020-09-26
Expected to finish
2022-07-28
Last updated by the study team
2023-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.